Is XRAY Stock Undervalued?
Dentsply Sirona (NASDAQ:XRAY) is a large manufacturer of dental equipment…
Sell
21
IOVA Quote, Financials, Valuation and Earnings
Last price:
$2.22
Seasonality move
:
-9.87%
Day range:
$2.18 - $2.26
52-week range:
$1.64 - $12.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.92x
P/B ratio:
1.16x
Volume:
7M
Avg. volume:
21.2M
1-year change:
-80.4%
Market cap:
$806.9M
Revenue:
$164.1M
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingIovance Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 4 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $9.10, Iovance Biotherapeutics, Inc. has an estimated upside of 308.07% from its current price of $2.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing -- downside risk from its current price of $2.23.
Fair Value
-
According to the consensus of 10 analysts, Iovance Biotherapeutics, Inc. has 308.07% upside to fair value with a price target of $9.10 per share.
IOVA vs. S&P 500
-
Over the past 5 trading days, Iovance Biotherapeutics, Inc. has overperformed the S&P 500 by 0.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Iovance Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Iovance Biotherapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Iovance Biotherapeutics, Inc. reported revenues of $60M.
Earnings Growth
-
Iovance Biotherapeutics, Inc. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Iovance Biotherapeutics, Inc. reported earnings per share of -$0.33.
Enterprise value:
558.9M
EV / Invested capital:
0.00x
Price / LTM sales:
2.92x
EV / EBIT:
--
EV / Revenue:
2.31x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$26.1M
Return On Assets:
-41.13%
Net Income Margin (TTM):
-161.44%
Return On Equity:
-52.43%
Return On Invested Capital:
-48.2%
Operating Margin:
-189.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $238K | $32.8M | $241.5M | $31.1M | $60M | |
| Gross Profit | -$24.3M | -$40.8M | $26.1M | -$5.6M | -$3M | |
| Operating Income | -$428.4M | -$459.3M | -$410.6M | -$101.9M | -$113.8M | |
| EBITDA | -$403.9M | -$418.9M | -$364.8M | -$91.1M | -$101.8M | |
| Diluted EPS | -$2.24 | -$1.67 | -$1.23 | -$0.34 | -$0.33 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $666.6M | $431.6M | $274.9M | $482.3M | $422.5M | |
| Total Assets | $852.8M | $610.9M | $757.3M | $964.3M | $907.4M | |
| Current Liabilities | $60.5M | $64.2M | $88.6M | $93.6M | $129.2M | |
| Total Liabilities | $108.4M | $138.2M | $178.7M | $195.8M | $208.9M | |
| Total Equity | $744.4M | $472.7M | $578.6M | $768.5M | $698.5M | |
| Total Debt | $52.3M | $80.5M | $80.7M | $81.7M | $53.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$335.1M | -$388.8M | -$303.4M | -$98.4M | -$67.4M | |
| Cash From Investing | $70.8M | -$223.1M | $4.6M | $40.2M | $13.8M | |
| Cash From Financing | $450M | $550.2M | $200.8M | $152.8M | $13.2M | |
| Free Cash Flow | -$354.7M | -$400.5M | -$323.5M | -$98.9M | -$74.9M | |
IOVA
Sector
Market Cap
$806.9M
$32.4M
Price % of 52-Week High
--
49.8%
Dividend Yield
0%
0%
Shareholder Yield
-35.35%
-1.37%
1-Year Price Total Return
-80.4%
-23.68%
Beta (5-Year)
0.822
0.574
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.45
200-day SMA
Sell
Level
$4.30
Bollinger Bands (100)
Sell
Level
1.82 - 3.04
Chaikin Money Flow
Sell
Level
-234M
20-day SMA
Sell
Level
$2.46
Relative Strength Index (RSI14)
Sell
Level
43.38
ADX Line
Sell
Level
14.38
Williams %R
Neutral
Level
-73.6527
50-day SMA
Sell
Level
$2.34
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-33.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2977)
Sell
CA Score
(Annual)
Level (-1.2764)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.6818)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Stock Forecast FAQ
In the current month, IOVA has received 5 Buy ratings 4 Hold ratings, and 1 Sell ratings. The IOVA average analyst price target in the past 3 months is $9.10.
-
Where Will Iovance Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Iovance Biotherapeutics, Inc. share price will rise to $9.10 per share over the next 12 months.
-
What Do Analysts Say About Iovance Biotherapeutics, Inc.?
Analysts are divided on their view about Iovance Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Iovance Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Iovance Biotherapeutics, Inc.'s Price Target?
The price target for Iovance Biotherapeutics, Inc. over the next 1-year time period is forecast to be $9.10 according to 10 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is IOVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Iovance Biotherapeutics, Inc. is a Buy. 5 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IOVA?
You can purchase shares of Iovance Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Iovance Biotherapeutics, Inc. shares.
-
What Is The Iovance Biotherapeutics, Inc. Share Price Today?
Iovance Biotherapeutics, Inc. was last trading at $2.22 per share. This represents the most recent stock quote for Iovance Biotherapeutics, Inc.. Yesterday, Iovance Biotherapeutics, Inc. closed at $2.23 per share.
-
How To Buy Iovance Biotherapeutics, Inc. Stock Online?
In order to purchase Iovance Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Clarivate Stock Undervalued?
Clarivate (NYSE:CLVT) is an analytics and research business whose services…
Is Dick’s Sporting Goods Stock Undervalued?
The market still prices Dick’s Sporting Goods (NYSE: DKS) at…
Stock Ideas
Buy
61
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Alerts
Sell
30
MRVL alert for Sep 2
Marvell Technology, Inc. [MRVL] is down 0.14% over the past day.
Buy
62
ZEPP alert for Sep 2
Zepp Health Corp. [ZEPP] is up 0.49% over the past day.
Buy
78
AMBA alert for Sep 2
Ambarella, Inc. [AMBA] is down 7.87% over the past day.
